Authors
Latest:
Long-Acting Lipoglycopeptides for the Treatment of Severe InfectionsLong-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.
Latest:
340B Drug Pricing Program: What Is It and Why Is It Important?The 340B program has had a great impact on access to HIV treatment and prevention services in the US.
Latest:
Mixed Fungal Brain AbscessClinicians review a patient case including diagnosis, treatment, and follow-up.
Latest:
MRNA COVID-19 Vaccines and Male FertilityAccording to a small study, the Moderna and Pfizer COVID-19 vaccines do not impact male fertility.
Latest:
Multidisciplinary Perspectives on HIV TreatmentA multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
Latest:
ViiV Healthcare Presents Potential Long-Acting HIV TherapiesPhase 1 data on VH184, a third-generation integrase strand transfer inhibitor, and VH499, a novel HIV-1 capsid inhibitor, highlighting their antiviral potency, safety profiles, and potential for long-acting injectable formulations.
Latest:
Addressing Neonatal CNS Infections: Case Report of Ceftaroline Therapy in Preterm Infant With Ventriculosubgaleal ShuntHere is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.
Latest:
COVID-19 Booster Shots and the FutureKey opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
Latest:
How Temperature-Sensitive Traits Could Explain Why E coli's Lookalike Goes UndetectedAt ASM Microbe 2025, Pelumi Oladipo discusses E marmotae’s reduced motility, misidentification as E coli, and the diagnostic tools closing the gap.
Latest:
Long-Acting Antiretroviral Therapies for HIV Treatment and PreventionMore treatment options and modalities are now available for patients.
Latest:
Longhorn Vaccines Develops Sepsis Vaccine Targeting Key ToxinsThis composite peptide vaccine targets key bacterial toxins to prevent sepsis, enhance antibiotic efficacy, reduce inflammation in diseases and cancer, with further data expected soon.
Latest:
Identifying Disparities in Sepsis Diagnosis for Unbiased CareRisk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.
Latest:
Future Directions for Managing COVID-19 and InfluenzaGeorge Loukatos, MD, shares clinical pearls for the management of the SARS-CoV-2 and influenza viruses.
Latest:
Challenges in the Management of Mycobacterium abscessus ComplexThis pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
Latest:
Cabotegravir Combined With Broadly Neutralizing Antibodies Maintains Undetectable HIVIn a long-acting dose regimen, an investigational antibodies treatment is a potent antiviral that can function as a component of a complete antiretroviral regimen.
Latest:
A Faster, More Powerful Way to See DiseaseYale School of Medicine’s Department of Pathology has embraced the booming field of digital pathology, where digital scanners and AI are improving speed and accuracy.
Latest:
Contemporary Issues on the Treatment of Women Living with HIV in the USThe increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.
Latest:
From Pandemic to EndemicA research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.
Latest:
So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
Latest:
The ART of Implementing an Antiretroviral Stewardship ProgramBy addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.
Latest:
cUTI Roundtable: The Latest Therapeutic DevelopmentsThe third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.
Latest:
What We Know But Still Have to Learn About Long COVIDDespite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
Latest:
Rethinking Fungal Blood Cultures in Sepsis WorkupsLogan Brock, PharmD, presents data at MAD-ID, showing limited diagnostic yield from routine fungal cultures and delayed results compared with standard methods.
Latest:
A Long-Acting Injectable for the Treatment of Candida spp InfectionsIn the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.
Latest:
'Tis the Season: Addressing Tick-Borne IllnessesAndrew Handel, MD, discusses prevention, how to remove ticks, and the burden of Lyme disease in certain populations.
Latest:
Rifaquizinone: A Novel Rifamycin-Quinolone Hybrid AntibioticRifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.
Latest:
Decoding Malaria Parasites to Aid in Potential Treatments and VaccinesThe Johns Hopkins Malaria Research Institute’s work in this area is looking to find ways to identify, for the first time, every single gene in the genome of malaria parasites, which could lead to the development of new treatments or vaccines.
Latest:
Molecular Diagnostics for Bacterial Pneumonia Need Testing StewardshipOngoing education and proven outcomes need to aid this form of testing.
